PR Newswire Clinical TrialsOriginal article
Theranica Announces Landmark Coverage Milestone as Nerivio® Exceeds Half of the U.S. Insured Population
RegulatoryNerivioPositive
AI Analysis
Summary
Theranica's Nerivio, an FDA-cleared wearable Remote Electrical Neuromodulation device for migraine treatment, achieved coverage parity with leading prescription migraine drugs after exceeding 158 million covered lives nationwide through recent payer coverage expansions.
Outcome Details
FDA-cleared device achieved coverage by 158 million insured lives
Importance:6/10
Sentiment:
0.80
FDA clearancewearable deviceremote electrical neuromodulationpayer coveragemigraine treatment
Read the original article
Published by PR Newswire Clinical Trials on July 9, 2026 1:06 PM